1S70.F Cartesian Therapeutics, Inc.
- Market cap
- EUR 178M
- P/E
- -
- P/B
- 31.72x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 1S70.F undervalued?
Graham numberThe Graham number of Cartesian Therapeutics, Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Cartesian Therapeutics, Inc. fundamental analysis
No fundamental analysis for Cartesian Therapeutics, Inc. yet.
Cartesian Therapeutics, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Cartesian Therapeutics, Inc.
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare p…
Full company profileCartesian Therapeutics, Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Cartesian Therapeutics, Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 85.1M | 111M | 26.0M | 38.3M | 2.40M | 0.00 |
| Operating Income | -4.60M | 14.5M | -85.7M | -36.3M | -86.7M | -108M |
| EBITDA | - | 39.1M | -235M | -76.0M | -83.7M | -22.9M |
| Net Income | -25.7M | 35.4M | -220M | -77.4M | -130M | -46.5M |
| EPS | -6.23 | 6.94 | -41 | -3.00 | -5.01 | -1.53 |
| Balance Sheet | ||||||
| Total Assets | 160M | 166M | 305M | 435M | 296M | 294M |
| Total Liabilities | 137M | 72.1M | 745M | 442M | 423M | 425M |
| Shareholders' Equity | 22.5M | 93.8M | -440M | -6.80M | -126M | -130M |
| Cash & Short-term Investments | 114M | 106M | 76.9M | 213M | 125M | 123M |
| Cash Flow | ||||||
| Operating Cash Flow | -60.4M | -31.6M | -51.2M | -23.7M | -73.9M | -94.6M |
| Capital Expenditure | 1.09M | 1.20M | 206K | 9.09M | 5.45M | 987K |
| Free Cash Flow | -61.5M | -32.8M | -51.4M | -32.8M | -79.4M | -95.6M |
| Ratios | ||||||
| ROE | -114.1% | 37.7% | - | - | - | - |
| ROA | -16.1% | 21.3% | -72.0% | -17.8% | -44.0% | -15.8% |
| Net Profit Margin | -30.2% | 31.9% | -844.9% | -202.3% | -5,436.0% | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Cartesian Therapeutics, Inc. dividends
Cartesian Therapeutics, Inc. has not paid dividends in the last 5 fiscal years.
Last stock split: 1:30 on Apr 5, 2024.
Who owns Cartesian Therapeutics, Inc.
- Insiders 51.71%
- Institutions 29.30%
- Public & others 18.99%
- Shares outstanding 30.5M
- Free float 11.7M
Cartesian Therapeutics, Inc. company profile
- Company name
- Cartesian Therapeutics, Inc.
- Ticker
- 1S70.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 75
- Fiscal year end
- December
- Address
- 7495 New Horizon Way, Frederick, MD, United States, 21703
- Phone
- 301 348 8698
- Website
- cartesiantherapeutics.com
About Cartesian Therapeutics, Inc.
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, an autologous B cell maturation antigen (BCMA) that is in phase 1 trials directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.
Cartesian Therapeutics, Inc. management
6- Dr. Carsten Brunn Ph.D.President, CEO & Chairman of the Board · born 1971
- Mr. Blaine T. DavisChief Financial Officer · born 1974
- Dr. Emily English Ph.D.Chief Operating Officer · born 1980
- Ms. June SeymourChief Accounting Officer · born 1978
- Mr. Matthew Bartholomae J.D.General Counsel & Secretary
- Dr. Peter G. Traber M.D.Head of R&D · born 1955